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ABSTRACT

The United States District Court for the Southern District of New York recently held
in Assoeiation for Molecular Pathology v. United States Patent & Trademark Offiee
that Myriad's patent claims directed to isolated DNA molecules encoding human
breast cancer susceptibility genes BRCA1/2 are not patent-eligible subject matter.
Even though the court construed that the patent claims are directed to tangible
chemical compounds, the overriding importance of unclaimed DNA sequence
information renders claimed molecules as unpatentable products of nature. While
the immediate impact of this decision is limited to Myriad's patents-in-suit, this
decision reflects the concern about the adverse effects of human gene patents in
genetic testing. This comment analyzes the patent-eligibility and constitutionality of
human gene patents. As alternatives to a total ban on human gene patents, this
comment proposes narrowly tailored legislation to balance the public's interest in
access to human gene patents and the biotech industry's incentives to invest capital
to translate basic research to commercial products that ultimately benefit the public.
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"Whatevertheir validity, the contentions now pressedon us should be addressedto
the politicalbranehes of the Government, the Congress and the Executive, and not to
the courts."
1
J. Burger, Diamond v. Charkarabarty

INTRODUCTION

The United States Patent and Trademark Office ("USPTO") has long granted
patents that claim inventions based on human genes. 2 In 2007, Rep. Xavier Becerra
introduced the Genomic Research and Accessibility Act to ban human gene patents
but this legislation received little support.3 On May 12, 2009, the Association for
Molecular Pathology ("AMP") filed a lawsuit against the USPTO, Myriad Genetics
("Myriad"), and the University of Utah Research Foundation, challenging the validity
of Myriad's gene patents. 4 Myriad holds, either through assignment or exclusive
license, numerous U.S. patents on isolated DNA molecules encoding the human
breast cancer susceptibility genes BRCA1 and BRCA2 (collectively "BRCA1/2") and
diagnostic methods using these isolated DNA molecules to determine a predisposition
to hereditary breast cancer. 5 In its complaint, AMP challenged patent-eligibility and
constitutionality of Myriad's patents, stating that human genes are products of
6
nature, laws of nature, and abstract ideas.
On March 29, 2010, Judge Robert Sweet of the United States District Court for
the Southern District of New York held that Myriad's patent claims directed to
isolated DNA molecules encoding human BRCA1/2 are not patent-eligible and "[tihis
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Department of Surgery, Northwestern University Medical School, Ph.D. Neuroscience/Cell and
Molecular Biology, Northwestern University. B.S. Biology, Ewha Womans University, Korea. I
would like to thank my editors, Jonathan Pope and Noreen Coady, and the staff of The John
Marshall Review of Intellectual Property Law for their editorial assistance. I would also like to
thank Kevin Noonan (McDonnell Boehnen Hulbert & Berghoff L.L.P.) and Scott McDonald (Mars
Inc.) for their constructive suggestion.
1 447 U.S. 303, 317 (1980).
2 SECRETARY'S ADVISORY COMMITTEE ON GENETICS, HEALTH AND SOCIETY, REVISED DRAFT
REPORT ON GENE PATENTS AND LICENSING PRACTICES AND THEIR IMPACT ON PATIENT ACCESS TO

GENETIC TESTS 57 (Feb. 5, 2010) ("[T]he USPTO begins issuing patents on isolated nucleic acid
molecules whose sequences correspond to genes in 1992.") available at http://oba.od.nih.gov/oba/
SACGHS/SACGHS%/o20Patents%/20Report%/o2OApproved% 2 02-5-20010.pdf (last visited Apr. 20,
2010) [hereinafter SACGHS Report].
3 Genomic Research and Accessibility Act, H.R. 977, 110th Cong. § 2 (2007).
4 Complaint at
32, Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No.
09CV04515, 2009 WL 1343027 (S.D.N.Y. May 12, 2009) (challenging the validity of 15 claims in 7
patents) [hereinafter AMP Complaint].
Id. at 31.
(3Id. at
102-03.
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conclusion is driven by the overriding importance of DNA's nucleotide sequence to
both its natural biological function as well as the utility associated with DNA in its
isolated form." 7 The district court's decision was based upon the findings that "DNA
represents the physical embodiment of biological information, distinct in its essential
characteristics from any other chemical found in nature" and that "DNA's existence
in an 'isolated' form alters neither this fundamental quality of DNA as it exists in the
body nor the information it encodes."8 However, the district court, invoking the
doctrine of constitutional avoidance, dismissed the constitutional claims against the
USPTO. 9 On June 16, 2010, Myriad filed a Notice of Appeal to the Court of Appeals
for the Federal Circuit ("Federal Circuit").1 The immediate impact of the district
court's decision is limited because "the decision made in a district court does not
apply to gene patents other than the ones it considered and its value as a precedent
for other courts is limited."11 However, the district court's decision, if upheld in the
Federal Circuit, would have implications reaching far beyond Myriad's patents-in12
suit by affecting the validity of numerous other human gene patents.
This comment examines the ongoing legal and policy issues concerning human
gene patents in view of Assoeiation for MolecularPathology v. United States Patent
& Trademark Office ("Myriad').13 Part I examines the current legal basis for
granting human gene patents and policy recommendations for exercising patent
rights in the marketplace. Part I also discusses the recent district court's decision in
Myriad. Part II analyzes the patent-eligibility and constitutionality of Myriad's gene
patents-in-suit.
Part III advocates narrowly-tailored legislation for compulsory
licensing and for exemption from patent infringement remedies for human genetic
diagnostic testing.

I.BACKGROUND
Genetic research was revolutionized by the discovery that deoxyribonucleic acid
("DNA") embodies the genetic information of every living organism. 14 Scientists have
identified human genes and their DNA sequences that have diagnostic and
therapeutic values. 15 The USPTO has granted patents relating to newly identified
7 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515, 2010 WL
1233416, *42 (S.D.N.Y. Mar. 29, 2010) (amended April 5, 2010).
8 Id. at *1.
9
Id. at *50-51.
10Notice of Appeal to the Federal Circuit, Ass'n for Molecular Pathology v. U.S. Patent &
Trademark Office, No. 09 Civ. 4515 (S.D.N.Y. June 16, 2010).
11Andrew Pollack, After Patent on Genes is Invalidated, Taking Stock, N.Y. TIMES, March 31,
2010, at B1.
12 See John Schwartz & Andrew Pollack, Judge Invalidates Human Gene Patent,N.Y. TIMES,
Mar. 30, 2010, at B1.
1' 2010 WL 1233416 (S.D.N.Y. Mar. 29, 2010).
14 J.D. Watson & F.H.C. Crick, Molecular Structure of Nucleic Acid.* A Structure for
Deoxyribose Nucleic Acid, 171 NATURE 737, 737-38 (1953); J.D. Watson & F.H.C. Crick, Genetic
Implications of the Structure ofDeoxyribonucleicAcid, 171 NATURE 964, 964-67 (1953).
15 See NAT'L RESEARCH COUNCIL OF THE NAT'L ACADEMIES, REAPING THE BENEFITS OF
GENOMIC AND PROTEOMIC RESEARCH: INTELLECTUAL PROPERTY RIGHTS, INNOVATION, AND PUBLIC
HEALTH 32-49 (Stephen A. Merrill & Anne-Marie Mazza, eds., National Academies Press 2006)
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genes that encode therapeutic proteins and genes that are linked to a predisposition
for rare diseases. 16 The following section examines the current legal basis for human
gene patents and policy recommendations for exercising patent rights in the
marketplace. This section, then discusses the controversy surrounding Myriad's gene
patents.

A. CurrentLegalBasis for Human Gene Patents
The U.S. Constitution authorizes Congress to enact laws "to promote the
Progress of Science and useful Arts."17 Congress enacted the first Patent Act in
179018 and most recently revised the Act in 1952.19 This section focuses on patenteligibility under the Patent Act of 1952 and the constitutionality of human gene
patents.

1. Patent-Eligibilityof Human Gene Patents
According to the Patent Act of 1952, categories of patent-eligible subject matter
include "any ... process, machine, manufacture, or composition of matter .... "20
The Supreme Court has broadly construed statutory subject matter "to include
anything under the sun that is made by man."21 Nonetheless, the Supreme Court
held that "laws of nature, physical phenomena, and abstract ideas" are excluded from
patent-eligible subject matter. 22 In Diamond v. Chakarabarty,the Supreme Court
held that a genetically engineered bacterium carrying multiple oil-degrading
plasmids was patent-eligible. 23 The Supreme Court concluded that "[p]lasmids are
hereditary units physically separate from the chromosomes of the cell" and
Chakrabarty produced "a new bacterium with markedly different characteristics
from any found in nature" by introducing multiple oil-degrading plasmids into a
bacterium, which itself has no capacity for degrading oil.24
Although the Supreme Court has not yet addressed patent-eligibility of human
genes, courts have implicitly recognized that isolated DNA molecules encoding
[hereinafter NAT'L RESEARCH COUNCIL'S REPORT]; NUFFIELD COUNCIL ON BIOETHICS, THE ETHICS
OF PATENTING DNA 5 (2002), available at http://www.nuffieldbioethics.org/fileLibrary/pdf/
theethicsofpatentingdna.pdf [hereinafter NUFFIELD COUNCIL'S REPORT].
16 See, e.g., U.S. Patent No. 4,666,828 col. 13 11. 25-30 (filed Aug. 15, 1984) (claiming the
method of genetic testing of Huntington's Disease); U.S. Patent No. 4,703,008 col. 39 11. 62-68 (filed
Nov. 30, 1984) (claiming the isolated DNA molecules encoding human erythropoietin).
17 U.S. CONST. art. I, § 8, cl. 8.
ISAn Act to promote the progress of useful Arts, ch. 7, 1 Stat. 109 (1790).
19 Act of 1952, ch. 950, 66 Stat. 792 (1952) (codified as amended under Title 35 of the United
States Code).
20 66 Stat. at 797 (codified as 35 U.S.C. § 101).
21 Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (quoting Hearing on HR. 3760 Before
Subeomm. No. 3 ofH. Comm. on the Judiciary,82d Cong. 37 (1951) (statement of P.J. Frederico, a
principal draftsman of Act of 1952)).
22

Id.

23 Id.
24 Id.

at 305, 310.
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specific genes are patent-eligible. 25 The USPTO has granted human gene patents
claiming isolated and purified DNA molecules and any new use of these molecules
subject to other statutory requirements for patentability. 26 In Amgen v. Chugai
Pharmaeeutieal Co., the United States District Court for the District of
Massachusetts determined "what the invention [was]" before ruling on anticipation of
the claim-in-suit. 27 The court rejected Amgen's contention that the claimed invention
was "the DNA sequence encoding human erythropoietin (EPO)" because "the DNA
sequence encoding human EPO is a non-patentable natural phenomenon 'free to all
men and reserved exclusively to none."' 28 The court construed the claimed invention
as 'the purified and isolated' DNA sequence encoding EPO."29 The Federal Circuit
affirmed the district court's ruling on the ground that "[t]he subject matter of claim
was the novel purified and isolated sequence which codes for EPO" and the Amgen
30
scientists were the first to isolate and characterize the EPO gene.
Such a decision is consistent with upholding patents on new and useful chemical
compounds isolated or purified from natural substances. 31 For example, in Merck &
Co. v. Olin Mathieson Chemical Corp., the Court of Appeals for the Fourth Circuit
held that "there is nothing in the language of the Act which precludes the issuance of
patent upon a 'product of nature' when it is a 'new and useful composition of matter,"'
32
subject to other statutory requirements for patentability.

2. ConstitutionalityofHuman Gene Patents
The Constitution grants Congress broad power to legislate "to promote the
Progress of Science and useful Arts." 33 The considerable medical benefits of human
gene-based inventions are not in dispute, but there are sharply divided views on
whether human gene patents promote scientific progress. 34
While some
commentators believe that human gene patents stimulate scientific progress by

25 See

In re Kubin, 561 F.3d 1351, 136 (Fed. Cir. 2009) (addressing the obviousness of isolated

DNA patents); Amgen, Inc. v. Chugai Pharma. Co., 927 F.2d 1200, 1206 (Fed.Cir. 1991) (addressing

the novelty of isolated DNA patents).
26 United States Patent and Trademark Office Utility Examination Guidelines, 66 Fed. Reg.
1092, 1093 (Jan. 5, 2001).
2713 U.S.P.Q.2d (BNA) 1737, 1759 (D. Mass. 1989).
28 Id. (quoting Chakrabarty,447 U.S. at 309).
29 Jd
'30
Amgen, Inc. v. Chugai Pharma. Co., 927 F.2d at 1206.
31 See, e.g., In -reBergstrom, 427 F.2d 1394, 1402 (C.C.P.A. 1970) (upholding the patent claim
on purified prostaglandin as patent-eligible subject matter); Merck & Co. v. Olin Mathieson Chem.
Corp., 253 F.2d 156, 162-63 (4th Cir. 1958) (upholding the patent claim on vitamin B 12-active
composition as patent-eligible subject matter); Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95,

103 (S.D.N.Y. 1911) (upholding the patent claim on isolated and purified adrenalin as patent-eligible
subject matter).
32 253 F.2d 156, 161 (4th Cir. 1958).
33U.S. CONST. art. I, § 8, cl. 8.
34 See, e.g., NAT'L RESEARCH COUNCIL'S REPORT, supra note 15, at 2 ([P]atented
inventions ...rarely impose[] a significant burden for biomedical researchers."); Lori B. Andrews,
Genes and Patent Policy: Rethinking Intellectual PropertyRights, 3 NATURE REVS. GENETICS 803,
804 (2002) ('Gene patents ... hamper pharmacogenomic research.").
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attracting investment capital to develop commercial products,3 5 others think that
such patents inhibit translational research and hinder patients' access to the gene36
based inventions.
According to a report by the National Research Council ("NRC"), human gene
patents rarely impose significant burdens on biomedical research.3 7 In contrast, the
Nuffield Council on Bioethics reported that several case studies of human gene
38
patents relating to research tools and genetic testing have indicated adverse effects.
One survey reported that twenty-five percent of the surveyed scientists stopped
performing clinical genetic testing services because of human gene patents, with
Myriad's patents among the most frequently mentioned. 39 A more recent survey,
however, reported that human gene patents including Myriad's patents have no
40
obvious effects on the price of and patients' access to clinical genetic testing.

B. PolicyRecommendations for Exercising Gene PatentRights in the Marketplace
Although there is no evidence of systematic failure of the licensing practices of
gene patents, a few cases of exclusive licensing practices have generated criticism
that human gene patents have adverse effects on public health. 4 1 In 2005, the
National Institutes of Health ("NIH") issued the Best Practices for the Licensing of
Genomic Inventions. 42 The NIH recommended, whenever possible, non-exclusive
licensing should be pursued because non-exclusive licensing facilitates broad access
to gene patents. 43 Non-exclusive licensing is proper "[w]hen a genomic invention
represents a component part or background to a commercial development." 44 In
contrast, exclusive licensing is necessary when commercial development of
therapeutics requires investment by a private company. 45 Nevertheless, the same
gene patents could be licensed non-exclusively for other fields of use such as
46
diagnostic genetic testing.
In 2006, the NRC issued further recommendations on genomic research. 47 For
example, the NRC advocated an experimental use exemption from infringement for

'35Allen C. Nunnally et al., Genetic PatentProtectionin the Pharmaceuticaland Biotechnology
Industries. 8 COMMUNITY GENETICS 209, 215 (2005); Mike Stott & Jill Valentine, Gene Patenting
and MedicalResearch:A View from a PharmaceuticalCompany, 3 NATURE REVS. DRUG DISCOVERY
364, 364 (2004).
36 Andrews, supra note 34, at 804-05.
37 NAT'L RESEARCH COUNCIL'S REPORT, supranote 15, at 2.
'38NUFFIELD COUNCIL'S REPORT, supra note 15, at 70-73.

1)Mildred K. Cho et al., Effects of Patents and Licenses on the Provision of Clinical Genetic
Testing Services, 5 J. MOLECULAR DIAGNOSTICS 3, 5 (2003).
40 Robert Cook-Deegan et al., The Dangers of Diagnostic Monopolies, 458 NATURE 405, 405

(2009).

41 NAT'L RESEARCH COUNCIL'S REPORT, supranotel5, at 146.
42 Nat'l Institutes of Health, Best Practices for the Licensing of Genomic Inventions, 70 Fed.

Reg. 18413 (Apr. 11, 2005).
43Id. at 18415.
44 Id.

45 Id.
46 Id.
47 NAT'L RESEARCH COUNCIL'S REPORT, supranote 15, at 133-49.
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non-commercial and educational use of gene patents. 48 The NRC also advocated that
courts should decline to enjoin patent infringement under "the extraordinary
situations in which the restricted availability of genomic inventions threatens the
public health." 49 Further, the NRC recommended that patent owners who control
access to gene-based diagnostic tests should establish procedures "for independent
50
verification of test results."

C. Recent District Court's Decisionin Association for Molecular
Pathology v. United States Patent & Trademark Office
Myriad's gene patents and its exclusive licensing practices have attracted
significant negative media coverage. 51 Myriad holds, either through assignment or
exclusive license, numerous U.S. patents on the human breast cancer susceptibility
52
genes BRCA1/2 that are linked to a predisposition to hereditary breast cancer.
Myriad is the sole clinical provider of full-sequence of BRCA1/2 testing in the United
States. 53 Although Myriad has not enforced its patents against academic research
institutions, Myriad has aggressively enforced its patents against providers of
commercial diagnostic testing. 54 For example, Myriad has sent cease and desist
letters, stating that clinical diagnostic testing must be done through Myriad's
laboratories or Myriad licensees. 55 Myriad has also engaged in litigation to prevent
others from performing clinical diagnostic testing.56
On May 12, 2009, AMP requested declaratory judgment that Myriad's patents
on human BRCA1/2 are invalid under 35 U.S.C. § 101 because Myriad's patents
57
claimed products of nature, manifestations of the laws of nature and abstract ideas.
AMP further sought declaratory judgment that Myriad's patents are unconstitutional
because the USPTO's policy of granting human gene patents violates Article I,
58
section 8, clause 8 and the First Amendment of the Constitution.
Myriad's patents-in-suit include two groups of claims- composition of matter
and method claims. 59 Myriad's composition of matter claims are directed to isolated
DNA molecules encoding normal or mutant forms of human BRCA1/2.6o A
representative of these claims is claim 1 of U.S. Patent 5,747,282:

Id. at 144-45.
49 Id. at 147.
5oId. at 149.
48

51Timothy Caulfield et al., Myriad and the Mass Media.* The Coverage of a Gene Patent
Controversy,9 GENETICS IN MEDICINE 850, 853 (2007).
52 AMP Complaint, supra note 4, at
31.
5 Id. at
28.
54 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 669 F.Supp.2d. 365, 37879 (S.D.N.Y. Nov. 2, 2009).
55 Id
,1cId. at 379.
57 AMP Complaint, supra note 4, at
102.
58 Id. at
103.
59 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515, 2010 WL
1233416, at *28-*29 (S.D.N.Y. Mar. 29, 2010) (amended April 5, 2010).
6o Id. at *28.
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1. An isolated DNA coding for a BRCA1 polypeptide, said polypeptide
61
having the amino acid sequence set forth in SEQ ID NO:2.
Myriad's method claims are directed to diagnostic methods for determining a
predisposition to breast cancer using isolated DNA molecules encoding human
BRCA1/2.62 A representative of these claims is claim 1 of U.S. Patent 5,709,999:
1. A method for detecting a germline alteration in a BRCA1 gene, said
alteration selected from the group consisting of the alterations set forth
in Tables 12A, 14, 18 or 19 in a human which comprises analyzing a
sequence of a BRCA1 gene or BRCA1 RNA from a human sample or
analyzing a sequence of BRCA1 cDNA made from mRNA from said
human sample with the proviso that said germline alteration is not a
deletion of 4 nucleotides corresponding to base numbers 4184-4187 of
63
SEQ ID NO:1.
64
AMP moved for summary judgment to declare Myriad's patents-in-suit invalid.
In response, Myriad moved for summary judgment to dismiss AMP's complaint on
the ground that "[tihe difference in the structural and functional properties of
isolated DNA" rendered Myriad's claim-in-suit patent-eligible.6 5 The USPTO also
moved for judgment on the pleadings based on the doctrine of constitutional
avoidance. 6 6 Judge Sweet of the United States District Court for the Southern
District of New York granted AMP's motion for summary judgment, denied Myriad's
cross-motion and granted the USPTO's motion for judgment on the pleadings. 67 The
court stated that "DNA represents the physical embodiment of biological
information" and that "Myriad's focus on the chemical nature of DNA, however, fails
to acknowledge the unique characteristics of DNA that differentiate it from other
chemical compounds." 68 Based on this reasoning, the court concluded that "[tihe
preservation of this defining characteristic of DNA in its native and isolated forms
mandates the conclusion that the challenged composition of matter claims are
directed to unpatentable products of nature."69 Similarly, Myriad's method claims

61U.S. Patent No. 5,747,282 col. 153 11. 56-58 (filed June 7, 1995) (claiming complementary
DNA (cDNA) encoding a 1863 amino acid sequence identified as SEQ ID NO:2).
Assn for Molecular Pathology,2010 WL 1233416, at *28-29.
U.S. Patent No. 5,709,999 col. 161 11.
17-25 (filed June 7, 1995).
61 Notice of Plaintiffs' Motion for Summary Judgment at 3,Ass'n for Molecular Pathology v.
U.S. Patent & Trademark Office, No.09 Civ. 4515 (S.D.N.Y.Aug.26, 2009).
6 Myriad Defendants' Memorandum of Law (1)in Support of Their Motion for Summary
Judgment and (2) in Opposition to Plaintiffs' Motion for Summary Judgment at 31, Ass'n for
Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515, 2009 WL 5785008
(S.D.N.Y.Dec.23, 2009) [hereinafter Myriad Brief].
66 Memorandum of Law in Support of Defendant United States Patent and Trademark Office's
Motion for Judgment on the Pleadings and in Opposition to Plaintiffs Motion for Summary
Judgment at 4,Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515,
2009 WL 5785024 (S.D.N.Y.Dec.24, 2009) [hereinafter USPTO Brief].
67 Assn forMoleeular Pathology, 2010 WL 1233416, at *1.
68 Id.at *1,*41.
6 Id.at *42.
62
63
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directed to comparisons of DNA sequences are abstract mental processes that
0
constitute unpatentable subject matter.

II.

ANALYSIS

The following section first examines the Supreme Court's statutory construction
of patent-eligibility under the Patent Act of 1952, followed by analysis of Myriad's
gene patents under this statutory construction. Then, this section examines the
constitutionality of Myriad's gene patents under Article I, section 8, clause 8 and the
First Amendment of the Constitution.

A. Patent-Eligibilityunder the PatentAct of 1952
1. Statutory ConstructionofPatent-Eligibility
The statutory language specifying the four categories of patent-eligible subject
matter under the Patent Act of 1952 is substantially the same as the language in the
Patent Act of 1793.71 A major change in the Patent Act of 1952 was the codification
of conditions for patentability- novelty under section 102 and nonobviousness under
section 103.72 Prior to the Patent Act of 1952, the inquiry for patent-eligible subject
73
matter was intertwined with the inquiry for patentability.
The Supreme Court has construed the Patent Act of 1952 to mean that "no
patent is available for a discovery, however useful, novel, and nonobvious, unless it
falls within one of the express categories of patentable subject matter of 35 U.S.C. §
101 .. . ."74 Section 101 provides, "[wihoever invents or discovers any new and useful
proeess, machine, manufacture, or composition of matter, or any new and useful
improvement thereof, may obtain a patent therefor[e], subjeet to the conditions and
requirements of this title."75 The Supreme Court has broadly construed section 101
because Congress chose "such expansive terms as 'manufacture' and 'composition of
matter,' modified by the comprehensive 'any'...." 76 This broad construction is
supported by the legislative history indicating that Congress intended statutory
subject matter "to include anything under the sun that is made by man."77 The Court,

70

Id. at *2.

71 An

Act to promote the progress of useful Arts, ch. 11, 1 Stat. 318, sec. 1 (1793); Act of 1952,
ch. 950, 66 Stat. 792, § 101 (1952); see A. Samuel Oddi, Regeneration in American Patent Law:
Statutory Subject Matter, 46 IDEA 491, 496-97 (2006) (indicating that the only modification was to
change the term "art" to "process").
72 35 U.S.C. §§ 102-03 (2006); see P.J. Federico, Commentary on the New PatentAet, 75 J. PAT.
& TRADEMARK OFF. SOC'Y 161, 178, 180 (1993).
73 Karl B. Lutz, The New 1952PatentStatute, 35 J. PAT. OFF. SOC'Y 155, 157-58 (1953).
74 Kewanee Oil Co. v. Bicron Corp., 416 U.S. 470, 486 (1974).
7" 35 U.S.C. § 101 (emphasis added).
76 Diamond v. Chakrabarty, 447 U.S. 303, 308 (1980).
77 Id. at 309 (quoting Hearing on HR. 3760 Before Subeomm. No. 3 of H. Comm. on the
Judiciary 82d Cong. 37 (1951) (statement of P.J. Frederico, a principal draftsman of Act of 1952)).
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however, held that section 101 does not embrace every discovery and "the laws of
78
nature, physical phenomena, and abstract ideas" are not patent-eligible.
In Diamond v. Chakrabarty, the Supreme Court determined whether the
claimed microorganism carrying oil-degrading plasmids constitutes a 'manufacture'
or 'composition of matter' within the meaning of section 101 without considering "the
other 'conditions and requirements' of the patent laws, such as novelty and
nonobviousness." 79 The Supreme Court defined the term "manufacture" as "the
production of articles for use for raw or prepared materials by giving these materials
new forms, qualities, properties, or combinations, whether by hand-labor or by
machinery."80 The Supreme Court construed "composition of matter" to include "all
compositions of two or more substances and ... all composite articles, whether they
be the results of chemical union, or of mechanical mixture, or whether they be gases,
fluids, powders or solids."8 1 Then, the Court held that the claimed microorganism
was patent-eligible because it was not directed to "a hitherto unknown natural
phenomenon, but to a non-naturally occurring manufacture or composition of
matter- a product of human ingenuity 'having distinctive name, character [and]
use."'

82

2. Are Myriad's Composition ofMatter Claims on IsolatedDNA Molecules Encoding
Normal or Mutant Formsof Human BRCA1/2 Patent-Eligible?
AMP contended that Myriad's composition of matter claims are drawn to
unpatentable products of nature because Myriad only discovered the pre-existing
human BRCA1/2 gene sequences. 83 AMP also contended that these claims are
unpatentable manifestations of the laws of nature because the claimed gene
sequences embody naturally-occurring genetic code that acts as a law of nature.8 4 In
response, Myriad contended that isolated DNA molecules encoding BRCA1/2 are
structurally and functionally different from naturally occurring BRCA1/2 DNA.85
In its recent opinion, the United States District Court for the Southern District
of New York first concluded that "products of nature" are well-established, judicially
created exceptions to patentable subject-matter. 86 Then, the court framed the issue
as "whether the claimed invention constitutes statutory subject matter ... or
whether the claimed invention instead falls within the judicially created 'products of
nature' exception to patentable subject matter, i.e., 'laws of nature, natural
phenomenon, and abstract idea."' 87 Relying on a number of cases predating Diamond
7s Id
79 Id. at 307, 307 n.5.
80

Id. at 308 (quoting Am. Fruit Growers, Inc. v. Brogdex Co., 283 U.S. 1, 11 (1931)).
(quoting Shell Dev. Co. v. Waston, 149 F. Supp. 279, 280 (D.D.C. 1957).
82 Id. at 309-10 (quoting Hartranft v. Wiegmann, 121 U.S. 609, 615 (1887)).
83 Plaintiffs' Memorandum of Law in Support of Motion for Summary Judgment at 19-26,
Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515, 2009 WL
3269113 (S.D.N.Y. Aug. 26, 2009) [hereinafter AMP Brief].
84 Id. at 26-29.
85 Myriad Brief, supra note 65, at 20-34.
86 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515, 2010 WL
SI Id.

1233416 at *33 n.40 (S.D.N.Y. Mar. 29, 2010) (amended April, 5, 2010).
87 Id. at *35.

[9:953 2010]

The John Marshall Review of Intellectual Property Law

v. Chakrabarty, the court concluded that "the Supreme Court precedent has
established that products of nature do not constitute patentable subject matter
absent a change that results in the creation of a fundamentally new product."88 The
court further concluded that Myriad's composition of matter claims-in-suit are
unpatentable products of nature because "[in light of DNA's unique qualities as a
physical embodiment of information," isolated DNA molecules encoding human
BRCA1/2 are not markedly different from naturally-occurring BRCA1/2 DNA.89
Despite the district court's opinion, it is not clear that products of nature are
well-established as judicially created exceptions to patent-eligibility because the
Supreme Court has never made a general statement that products of nature are not
patent-eligible.9 0 For example, in American Fruit Growers, Inc. v. Brodgex Co., the
Supreme Court held that a citrus fruit impregnated with borax to retard blue mold
was not a manufacture because "addition of borax to the rind of natural fruit does not
produce from the raw material an article for use which possesses a new or distinctive
form, quality, or property."9 1 Likewise, in American Wood-Paper Co. v. Fibre
DisintegratingCo., the Supreme Court held that "a pulp suitable for the manufacture
of paper, made from wood and other vegetable substances" was not a new
manufacture on the ground that the patent-in-suit was "void for want of novelty in
the manufacture patented" because "paper pulp obtained from various vegetable
substances was in common use before the original patent was granted." 92 Similarly,
in Coebrane v. Badisehe Anilin & Soda Fabrik, the Supreme Court held that an
artificial version of natural dye called alizarine was not a new composition of matter
because natural and artificial versions of alizarine were well-known. 93 In Merck &
Co. v. Olin Mathieson Chemical Corp., the Court of Appeals for the Fourth Circuit
("Fourth Circuit") concluded that the Supreme Court precedent has established that
a product derived from a new source or process is not patentable if the product is
substantially the same as a known product. 94 The Fourth Circuit further concluded
that "[there is nothing in the language of the Act which precludes the issuance of a
patent upon a 'product of nature' when it is a 'new and useful composition of matter"'
and reversed the district court's decision that vitamin B 12-active composition was
95
not patentable on the ground that it was a product of nature.
On the other hand, in Funk Bros. Seed Co. v. Kalo Inoeulant Co.,96 the Supreme
Court invalidated the patent claiming a mixture of mutually non-inhibitive strains of
bacteria because the patentee "[did] not create [a] state of inhibition or of noninhibition in the bacteria" and those qualities are "the manifestations of laws of
nature, free to all men and reserved exclusively to none." 97 Further, Justice
Id at *36.
Id at *42.
90 See, e.g., Am. Fruit Growers, Inc. v. Brodgex Co., 283 U.S. 1,11 (1931); Am. Wood-Paper Co v.
Fibre Disintegrating Co., 90 U.S. 566, 577-596 (1874); Cochrane v. Badische Anilin & Soda Fabrik,
88
89

111 U.S. 293, 311 (1884).
91 283 U.S. 1, 11 (1931).
92 90 U.S. 566, 577, 596 (1874).
93 111 U.S. 293, 311 (1884).

94 253 F.2d 156, 162-64 (4th Cir. 1958) (distinguishing the case at issue from American Wood
Paper and Coehrane.).
9 Id. at 161-63.
96 333 U.S. 127 (1948).
97 Id. at 130.
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Frankfurter, in his concurring opinion, concluded that the claim-in-suit was invalid
because it encompassed all combinations of compatible strains of bacteria. 98
Nonetheless, he stated that a specific combination of compatible strains identified
through experimental research is patentable. 99
Accordingly, whether Myriad's composition of matter claims-in-suit are patenteligible under 35 U.S.C. § 101 should depend on (1) whether they are within the
meaning of the four statutory categories of subject matter and (2) whether they do
not fall within judicially created exceptions to patent-eligible subject matter- "the
laws of nature, natural phenomenon and abstract ideas." 10 0 For the first issue,
Myriad's claims-in-suit are directed to "compositions of matter" in light of the district
court's claim construction. 10 1 Myriad's claims are directed neither to the naturally
occurring human BRCA1/2 genes nor to the naturally occurring human BRCA1/2
proteins but to the isolated DNA molecules encoding normal or mutant forms of
human BRCA1/2. 10 2 The court rejected AMP's construction of "DNA" as a "sequence
of nucleic acids, also referred to as nucleotides" and construed as "an acid- a tangible
chemical compound." 10 3 The court further construed "isolated DNA" as "a segment of
DNA nucleotides existing separate from other cellular components normally
associated with native DNA, including proteins and other DNA sequences comprising
the remainder of the genome, and includes both DNA originating from a cell as well
as DNA synthesized through chemical or heterologous biological means." 10 4 Thus,
Myriad's claims-in-suit are directed to tangible chemical compounds, which fall
10 5
within the Supreme Court's definition of "compositions of matter."
Additionally, Myriad's claims-in-suit may qualify as "manufacture" because
isolated DNA molecules encoding human BRCA1/2 are significantly different in
structure and function from the naturally-occurring human BRCA1/2 DNA. 106
Myriad's claims on isolated DNA encoding human BRCA1/2 are structurally different
from the native DNA because the claimed DNA molecules are separated from "other
cellular components normally associated with native DNA, including proteins and
other DNA sequences comprising the remainder of the genome" in a cell or are
synthesized DNA "through chemical or heterologous biological means." 10 7 Further, it
is undisputed that Myriad's claims-in-suit possess utility 108 because "unlike native
DNA in cells, the claimed isolated BRCA1/2 DNA molecules can be used as diagnostic
98 Id. at 133-34 (Frankfurter, J., concurring) (indicating that the claim-in-suit was directed to
all mixtures of compatible strains without adequately indentifying the particular combinations of
the strains that the patentee had discovered).
9 Id.
at 133 ("T]he packaging of a particular mixture of compatible strains
is ... patentable ... provided ... that the particular strains are identifiable and adequately
identified.").
100 See Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980); Diamond v. Diehr, 450 U.S. 175,
185 (1981).
101 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515, 2010
WL 1233416, at *31-*32 (S.D.N.Y. Mar. 29, 2010) (amended April 5, 2010).
102 See U.S. Patent No. 5,747,282 col. 153 11.57-59 (filed June 7, 1995).
103 Assn for MolecularPathology,2010 WL 1233416, at *31.
104 Id. at *32.
105 See Chakrabarty,447 U.S. at 308.
106 Soo Myriad Brief, supra note 65, at 20-34.
107 Assn for MoloeularPathology,2010 WL 1233416, at *32.
108 Id. at *35.
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probes and primers" in determining a predisposition to breast cancer. 109 Thus,
Myriad's claims-in-suit are directed to man-made manufacture, consistent with the
Supreme Court's definition to mean "the production of articles for use from raw or
prepared materials by giving to these materials new forms, qualities, properties, or
combinations, whether by hand-labor or by machinery."1 10
For the second issue, AMP contended that Myriad's claims-in-suit are judicially
excluded from patent-eligible subject matter because the claimed gene sequences
embody a law of nature similar to genes, which "embody a naturally-occurring
genetic code and acts as a law of nature." '1 As mentioned above, the district court
rejected AMP's claim construction to equate DNA with DNA sequence and concluded
that Myriad's composition of matter claims-in-suit are directed to "tangible chemical
compound[s]."112 In light of this claim construction, Myriad's claims-in-suit are not
directed to DNA sequence and thus do not encompass the law of nature, but rather
11 3
tangible chemical compounds that fall within the statutory subject matter.
However, the district court equated "products of nature" with the judicially
114
It
recognized exceptions- laws of nature, natural phenomenon, and abstract ideas.
concluded that "[i]n light of DNA's unique qualities as a physical embodiment of
information, none of the structural and functional differences cited by Myriad
between native BRCAI/2 DNA and the isolated BRCAI/2 DNA claimed in the
patents-in-suit render the claimed DNA 'markedly different.' 115
Further, the
district court stated that "[ti his conclusion is driven by the overriding importance of
DNA's nucleotide sequence to both its natural biological function as well as the
utility associated with DNA in its isolated form."11 6 Based on this reasoning, the
district court held that Myriad's composition of matter claims-in-suit are
"unpatentable products of nature."1 17

3. Are Myriad'sMethod Claims for Diagnostic Genetic Testing Patent-Eligible?
AMP, citing Justice Breyer's dissenting opinion in Lab. Corp. ofAm. Holdings v.
Metabolite Labs., Inc.,118 contended that Myriad's method claims are not patenteligible because the correlation between mutations in the human BRCA1/2 genes and
predispositions to breast cancer is a law of nature. 119 Alternatively, AMP contended
that Myriad's method claims are not patent-eligible in view of In re Bilski 120 because
these claims did not satisfy the machine-or-transformation test. 121 Myriad, relying

109 Myriad Brief, supra note 65, at 33.
110Chakrabarty,447 U.S. at 308.
111 AMP Brief, supra note 83, at 26-27.
112 Ass'n for MolecularPathology,2010 WL 1233416, at *31.
113See id. at "31-*32.
114 Id. at *35.
115Id. at *42.
116Id.
117

d.

548 U.S. 124 (2006) (dismissing writ of certiorari as improvidently granted).
119AMP Brief, supra note 83, at 30-31.
120 545 F.3d 943 (Fed. Cir. 2008), ert.granted,129 S. Ct. 2735 (2009).
121 AMP Brief, supra note 83, at 29 n.9.
118
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on Prometheus Labs., Inc. v. Mayo Collaborative Servs., 122 contended that its
method claims are patent-eligible in view of In re Bilski.123 The United States
District Court for the Southern District of New York concluded that Myriad's claims2
in-suit are not patent-eligible in view of In re Bilski.1
4 In In re Bilsk4, the Federal
Circuit held that a process is patent-eligible under section 101 if "(1) it is tied to a
particular machine or apparatus, or (2) it transforms a particular article into a
1 25
different state or thing."
Justice Breyer's dissenting opinion, in Lab. Corp., stated that diagnostic method
claims using the correlation between blood homocysteine levels and deficiencies in
vitamin B12 were unpatentable laws of nature.1 26 However, in Prometheus, the
Federal Circuit stated that the dissenting opinion is not controlling law and whether
a diagnostic method claim is a patent-eligible process depends on the machine-ortransformation test in view of In re Bllskl127 Then, the Federal Circuit held that
Prometheus' diagnostic method claims are patent-eligible because they are directed
to the "transformation ... of the human body following administration of a drug and
the various chemical and physical changes of the drug's metabolites that enable their
'1 28
concentrations to be determined."
Thus, the ultimate issue is whether Myriad's method claims-in-suit are directed
to patent-eligible processes in view of In re BilskLi 129 Myriad's method claims using
the correlation between mutations in the human BRCA1/2 genes and predispositions
to breast cancer may satisfy the machine-or-transformation test. 130 As Myriad
indicated, the initial transformation occurs when the patient's DNA or RNA is
isolated from his body.1 31 Further transformation occurs when a primer or probe
binds to the patient's isolated DNA or RNA before analyzing the correlation of the
patient's DNA sequence encoding human BRCA1/2 and a predisposition to breast
cancer. 13 2 Myriad indicated that these transformations were crucial to its method
133
claims.
However, the district court recently concluded that Myriad's claims-in-suit were
distinguishable from Prometheus' claims and failed the machine-or-transformation
test. 134 The district court stated that Myriad's method claims-in-suit "are directed
only to abstract mental process of 'comparing' or 'analyzing' gene sequences" and
"the transformative steps associated with isolating and sequencing DNA described in
135
the unchallenged dependent claims" cannot be incorporated into the claims-in-suit.
581 F.3d 1336 (Fed. Cir. 2009).
Myriad Brief, supra note 65, at 35.
124 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515, 2010
WL 1233416, at *49 (S.D.N.Y. Mar. 29, 2010) (amended April 5, 2010).
125 In re Bilsk4, 581 F.3d at 954.
126 Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 124 (2006) at 13738 (Breyer, J., dissenting).
127 Prometheus Labs., Inc. v. Mayo Collaborative Servs., 581 F.3d at 1342, 1346 n.3.
128 Id.at 1346.
129 See Ass'n for MolecularPathology,2010 WL 1233416, at *46.
130 See Myriad Brief, supra note 65, at 35.
131 Id. at 37.
122

123

132 Id.
133
134
135

Id. at 35.
Assn forMolecularPathology,2010 WL 1233416, at *48-49.
Id.at *48.
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The court further held that even if Myriad's method claims were construed to include
these physical transformations, "these transformations would constitute no more
than 'data-gathering step[s]' that are not 'central to the purpose of the claimed
136
process."'

B. ConstitutionalityofMyriad's Human Gene Patents
This section examines the constitutionality of Myriad's gene patents under
Article I, section 8, clause 8 and under the First Amendment.

1. Are Myriad's Gene Patents UnconstitutionalunderArticle I, Section 8, Clause 8?
AMP moved for summary judgment on the ground that the USPTO's policy of
granting human gene patents is unconstitutional under Article I, section 8, clause 8
because human gene patents in general and Myriad's patents in particular impede
rather than promote the progress of science. 137 The USPTO, relying on Ashwander v.
Tenn. Valley Authority13 8 and Spector Motor Serv., Inc. v. McLaughlin,1 3 9 moved for
judgment on the pleadings based on the doctrine of constitutional avoidance, which
states that courts should not reach unnecessary constitutional issues if a case can be
decided on statutory grounds or general law. 140 The United States District Court for
the Southern District of New York granted the USPTO's motion for judgment on the
pleadings and dismissed AMP's claim for constitutional violations without
141
prejudice.
Even though the district court did not address AMP's constitutional challenges,
AMP's contention has several flaws. First, Article I, section 8, clause 8 is irrelevant
to the USPTO's authority to grant human gene patents because this clause delegates
Congress the power "[to promote the Progress of Science and useful Arts, by securing
for limited Times to Authors and Inventors the exclusive Right to their respective
Writings and Discoveries .... "142 The Constitution further delegates Congress the
power "[tio make all Laws which shall be necessary and proper for carrying into
Execution the foregoing Powers .... "143 Under these powers, Congress enacted the
Patent Act of 1952 in general and specifically section 101.144 Congress has delegated
the USPTO power to grant patents under section 2.145

136

Id. at *49.

AMP Brief, supra note 83, at 38.
297 U.S. 288 (1936) (Brandeis, J., concurring).
139 323 U.S. 101 (1944).
140 USPTO Brief, supra note 66, at 4.
141 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515, 2010
WL 1233416, at *51 (S.D.N.Y. Mar. 29, 2010) (amended April 5, 2010).
142 U.S. CONST. art I, § 8, cl. 8.
137

138

143

Id. cl. 18.

Act of 1952, ch. 950, 66 Stat. 792, § 101 (1952).
145 35 U.S.C. § 2(a)(1) (2006).
144
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Further, the proper focus of constitutional challenges should be on the Patent
Act itself, rather than individual patents granted under the Act. 146 The USPTO
argued that the issue should be "whether there is a 'rational relationship' between
permitting patents on 'composition[s] of matter' and 'process[es]' . . . which cover the
gene-related patents and methods in the present case and Congress's legitimate
objective under the ... Clause." 147 Congress has a rational basis to employ broad
language in drafting section 101 to countenance human gene patents because "[a]
rule that unanticipated inventions are without protection would conflict with the core
concept of the patent law"1 48 Congress may freely amend section 101 to exclude
human genes from patent-eligible subject matter. 149 In fact, Congress recently
considered but did not enact legislation that would have banned human gene
150
patents.
Even if it is appropriate to focus on individual patents, there is no consensus
that human gene patents including Myriad's patents impede "the Progress of
Sciences and useful Arts."1 51 First, the Patent Act of 1952 promotes this progress by
offering an inventor the right to exclude others for a limited period, in exchange for a
complete disclosure of his invention. 152 Myriad contends that there are more than
8,600 research papers on BRCA1/2, including Myriad's 48 research papers, since
Myriad's discovery of the human BRCA1/2 genes. 153 Further, diagnostic methods for
determining a predisposition to breast cancer using human BRCA1/2 have been
improved. 154 For example, Myriad's initial diagnostic method was based on the
sequencing of the human BRCA1/2 genes but other scientists developed an improved
method based on the analysis of the rearrangement of these genes. 155 Recently, a
novel diagnostic method was developed by assaying the ability of human BRCA1/2
DNA molecules to produce functional human BRCA1/2 proteins, instead of assaying
156
the structure and sequences of human BRCA1/2 genes.
The Patent Act of 1952 also promotes the progress of science and useful arts by
1 57
encouraging investments to translate the inventions into commercial products.

146

Soo USPTO Brief, supra note 66, at 8.

H7 Id.
148 Diamond

v. Chakrabarty, 447 U.S. 303, 316 (1980).
See id. at 318.
150 Genomic Research and Accessibility Act, H.R. 977, 110th Cong. § 2 (2007).
151 NAT'L RESEARCH COUNCIL'S REPORT, supranote 15, at 2.
152 Giles S. Rich, The Relation Between Patent Practices and the Anti-Monopoly Laws, 24 J.
PAT. OFF. SOC'Y 159, 176-77 (1942).
153 Myriad Brief, supra note 65, at 46.
154 See,
e.g., Suhwan Chang et.al., Expression of Human BRCA1 Variants in Mouse ES Cells
Allows FunctionalAnalysis ofBR CA1 Mutations, 119 J. CLINICAL INVESTIGATION 3160, 3160 (2009);
Sergey G. Kuznetsov et.al., Mouse Embryonic Stem Cell-Based Functional Assay to Evaluate
Mutations in BRCA2, 14 NATURE MED. 875, 875 (2008); Sophie Gad et al., Identiscation of a Large
Rearrangement of the BRCA1 Gene Using Colour Bar Code on Combed DNA in an American
Breast/Ovarian Cancer FamilyPreviously Studied by DirectSequencing, 38 J. MED. GENETICS 388,
388 (2001); Lori S. Friedman et al., Confrmation of BRCA1 by Analysis of Germline Mutations
Linked to Breast and Ovarian Cancerin Ten Families.8 NATURE GENETICS 399, 399 (1994).
155 Gad, supra note 154, at 388.
156Chang, supra note 154, at 3160; Kuznetsov, supra note 154, at 875.
157 Rich, supra note 152, at 177.
14)
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Myriad contends that it would not have invested millions of dollars to commercialize
158
diagnostic testing for human BRCA1/2 without patent protection.

2. Are Myriad's Gene Patents Compatible with the FirstAmendment?
AMP moved for summary judgment to declare the USPTO's policy of granting
human gene patents unconstitutional under the First Amendment because human
gene patents "directly limit thought and knowledge." 159 AMP specifically contended
that the USPTO gave complete control over knowledge on the human BRCA1/2 genes
to Myriad. 160 The USPTO stated that Myriad's gene patents are by no means unique
in their impact on the First Amendment issue and that the issue "is not whether any
given patent might inhibit more speech than it promotes, but rather whether in
establishing a patent system that awarded such a patent, Congress somehow violated
the First Amendment." 161 The United States District Court for the Southern District
of New York dismissed AMP's constitutional challenges without prejudice based on
162
the doctrine of constitutional avoidance.
Even though the district court did not address AMP's constitutional challenge,
AMP's contentions have numerous flaws. First, the Patent Act of 1952 is compatible
with the First Amendment because the Patent Act requires the complete disclosure of
the claimed inventions in exchange for the right to exclude others. 163 Second, the
Patent Act of 1952 gives an inventor only the right to exclude others from making,
using, selling, offering for sale or importing the patented invention into the United
States.164
Even if it is appropriate to focus on individual patents, the USPTO did not grant
patents on thought or knowledge protected by the First Amendment. 165 The USPTO
has never granted patents claiming human gene sequence information. 166 Because
the USPTO had not granted an exclusive right on knowledge of human BRCA1/2
genes to Myriad, many scientists have published research papers describing variants
of human BRCA1/2 genes and correlations between the genetic variants and
1 67
predispositions to breast or ovarian cancer.
158 Myriad Brief, supra note 65, at 47.
159 AMP Brief, supra note 83, at 34.
160 Id. at 35.
161USPTO Brief, supra note 66, at 14, 16.
162 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515, 2010
WL 1233416, at *51 (S.D.N.Y. Mar. 29, 2010) (amended April 5, 2010).
163 Kewanee Oil Co. v. Bicron Corp., 416 U.S. 470, 480-81 (1974).
164 35 U.S.C. § 154 (2006).
165 See USPTO Brief, supra note 66, at 20.
166 Id. at 22.
107 See, e.g., Kangjian Wu et al., FunctionalEvaluation and CancerRisk Assessment of BRCA2
Unclassified Variants, 65 CANCER RESEARCH 417 (2005); Nebojsa Mirkovic et al., Structure-Based

Assessment of Missense Mutations in Human BRCA1." Implications for Breast and Ovarian Cancer
Predisposition,64 CANCER RESEARCH 3790 (2004); Ashok R. Venkitaraman, Cancer Susceptibility
and the Functions ofBRCA1 andBRCA2, 108 CELL 171 (2002); Ralph Scully & David M. Livingston,
In Search of the Tumor-SuppressorFunctions of BRCA1 and BRCA2, 408 NATURE 429 (2002); S.V.
Tavtigian et al., The Complete BRCA2 Gone andMutations in Chromosome 13q-inked -iandreds,12
NATURE GENETICS 333 (1996); Y. Miki et al., A Strong Candidatefor the Breast and Ovarian Cancer
Susceptibility Gene BRCA1, 266 SCIENCE 66 (1994).

[9:953 2010]

Gene Patenting Debate

III. PROPOSAL

While the recent district court's decision invalidating Myriad's gene patents has
a limited immediate legal effect, it will have far-reaching consequences of
invalidating thousands of human gene patents if the Federal Circuit upholds the
decision. 168 The district court acknowledged that its decision is "driven by the
overriding importance of DNA's nucleotide sequence to both its natural biological
function as well as the utility associated with DNA in its isolated form." 169 However,
the Supreme Court previously rejected the contention that the "Court should weigh
potential hazards in considering whether ... [the] invention is patentable subject
matter under § 101" because "[t]he choice we are urged to make is a matter of high
policy for resolution within the legislative process .... "170 Further, in a recent
human gene patenting debate, Dr. Wendy Chung, a plaintiff in Myriad, stated that
the real issue was not the validity of Myriad's gene patents, but exclusive licensing
practices used by Myriad with these patents.17 1 Dr. Chung further stated that there
would be a "middle ground" and suggested that patent pools and non-exclusive
licensing may be two alternatives to a total ban on human gene patents.17 2 The
following section advocates narrowly-tailored legislation that limits the enforcement
of human gene patent rights as alternative solutions to the total ban on human gene
patents. This section discusses legislation for compulsory licensing of human gene
patents and exemption from patent infringement remedies for human genetic
diagnostic testing as safeguards against exclusive licensing practices of human gene
patents.

A. Compulsory Licensing ofHuman Gene Patents
This section examines three examples of compulsory licensing practices and
proposes a narrowly-tailored compulsory licensing statute for human gene patents.

1. Framework of CompulsoryLicensing
Three examples of compulsory licensing practices are (1) "march-in" rights under
4
the Bayh-Dole Act;17 3 (2) refusal of injunctive relief under 35 U.S.C. § 154(a)(1);17
1 75
and (3) mandatory licensing under the Clean Air Act.
168 Pollack, supra note 11, at B1.
169 Ass'n for Molecular Pathology v.

U.S. Patent & Trademark Office, No. 09 Civ. 4515, 2010
WL 1233416, at *42 (S.D.N.Y. Mar. 29, 2010) (amended April 5, 2010).
170 Diamond v. Chakrabarty, 447 U.S. 303, 316-17 (1980).
171On Point with Tom Ashbrook, PatentingHuman Genes (Boston National Public Radio Jan
21, 2010), available at http://www.onpointradio.org/media-player?url=http://www.onpointradio.org/
2010/01/gene-patenting&title=Patenting+Human+Genes&pubdate=2010-01-21&segment=1.
172 Id.

173 Act of Dec. 12, 1980, Pub. L. No. 96-517, 94 Stat. 3015 (codified at 35 U.S.C. §§ 200-212); 35

U.S.C. § 203

(2006).
174 35 U.S.C. § 154(a)(1).
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The first example is "march-in" rights under the Bayh-Dole Act.17 6 The purpose
of the Bayh-Dole Act is to promote commercialization and public availability of
federally-funded inventions. 177 For this purpose, a federal agency may exercise
"march-in" rights by requiring the licensing of a funding recipient's inventions to a
third party in limited circumstances. 178 One of these limited circumstances occurs
when such action is "necessary to alleviate health and safety needs .... "179 The
"march-in" rights, however, create a potential problem of overlapping jurisdiction
between a federal agency and a court because the adversely affected party may
180
appeal the federal agency's decision to the Court of Federal Claims.

The second example occurs when a court declines to enjoin patent infringement
remedies.18 1 In eBay Inc. v. MereExchange, L.L. C., the Supreme Court held that a
statutory right to exclude under 35 U.S.C. § 154(a)(1) alone does not justify a general
rule that "a permanent injunction will issue once infringement and validity [of
patents] have been adjudged." 182 In Hynix Semiconductor Inc. v. Rambus Inc., the
United States District Court for the Northern District of California ordered
compulsory licensing after finding that injunctive relief was improper.183
The final example is mandatory licensing under the Clean Air Act.18 4 Before a
court orders compulsory licensing of a patent that is critical to control air pollution,
the Attorney General is required to determine that the patented invention is not
reasonably available; that there are no reasonable alternatives; and that the
unavailability of such rights may result in a substantial problem of competition to
create a monopoly.185

2. ProposedLegislation of Compulsory Licensing of Human Gene Patents
The legislation proposed here for compulsory licensing of human gene patents is
very narrow and its framework is based on "march-in" rights under the Bayh-Dole
Act and mandatory licensing under the Clean Air Act. Unlike "march-in" rights
under the Bayh-Dole Act, the proposed legislation applies to patents on inventions
that did not result from federal funding. 186 Before a court orders compulsory
licensing of specific human gene patents, the Attorney General should determine
that (1) the patented human gene-related inventions are not reasonably available; (2)
175 Clean Air Act, Pub. L. No. 84-159, 69 Stat. 322 (1955) (amended by Clean Air Amendments
of 1970, Pub. L. No. 91604, 84 Stat. 1676 (codified as amended at 42 U.S.C. §§ 7401-7626)); 42

U.S.C. § 7608.
176 35 U.S.C. § 203.
177 Id. § 200.
178 Id.§ 203(a).
§ 203(a)(2).
§ 203(b); see Barbara M. McGarey & Annette C. Levey, Patents, Products, and Public
Health: An Analysis of the Cl]ProMarch-InPetition, 14 BERKELEY TECH. L.J. 1095, 1106 (1999).
1S eBay Inc. v. MercExchange, L.L.C, 547 U.S. 388, 394 (2006); Hynix Semiconductor Inc. v.
Rambus Inc., 609 F.Supp.2d 951, 987 (N.D. Cal. 2009).
182 547 U.S. 388, 393-94 (2006).
183 609 F. Supp.2d 951, 987 (N.D. Cal. 2009).
184 42 U.S.C. § 7608 (2006).
185 Id.
179 d.

180 Id.

186

See 35 U.S.C. § 203.
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there are no reasonable alternatives; and (3) compulsory licensing is necessary to
alleviate public health needs. Alternatively, Congress could appoint a specific federal
agency for these determinations. For example, the Office of Science and Technology
Policy ("OSTP") would be a good candidate because Congress has previously directed
the OSTP to determine "the impact of federal policies ... on the innovation process
for genomic technologies." 18 7 Once the determinations have been made, the court
may require compulsory licensing to allow scientists and clinical researchers to use
specific human gene patents for patients' benefit. This proposal would not be
expeditious and would not address all problems associated with licensing practices.
It would be prudent, however, not to alter conventional licensing practices without a
determination whether it is necessary for diagnostic or therapeutic developments.

B. Exemption from PatentInfringement Remedies for
Human Genetic Diagnostic Testing
This section examines two examples of exemption from patent infringement
remedies and proposes an exemption from patent infringement remedies for human
genetic diagnostic testing.

1. Framework of Exemption from Infringement Remedies for Human Genetic
Diagnostic Testing
The Patent Act of 1952 has no general statutory exemption for experimental or
research use.1 8 8 In Madey v. Duke University,the Federal Circuit held that practice
of patented inventions at academic institutions does not shield these institutions
from patent infringement liability regardless of commercial implications or lack
thereof. 189 Nonetheless, Congress has provided statutory exemptions to patent
infringement and patent infringement remedies. 19
The first exemption is described in 35 U.S.C. § 271(e)(1).191 The Supreme Court
has construed this section to protect the use of patented pharmaceutical compounds
for the purpose of the submission of new compounds to the Food and Drug
Administration, but not for the purpose of general biomedical research. 192 The
second exemption described in 35 U.S.C. § 287(c)(1) applies to medical practitioners'
performance of patented medical or surgical procedures on patients. 193 This

Genomic Science and Technology Innovation Act of 2002, H.R. 3966, 107th Cong. sec. 3(a).
Act of 1952, ch. 950, 66 Stat. 792 (1952) (codified as amended under Title 35 of the United
States Code); see NAT'L RESEARCH COUNCIL'S REPORT, supra note 15, at 144; Jordan Paradise &
Christopher Janson, Decoding the Research Exemption, 7 NATURE REVIEW GENETICS 148, 150
(2006).
189 307 F.3d 1351, 1362 (Fed. Cir. 2002).
190 35 U.S.C. §§ 271(e)(1), 287(c)(1).
191 Id. § 271(e)(1).
192 Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193, 205 (2005).
193 35 U.S.C. §§ 287(c)(1)-(c)(2)(A).
187

188
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exemption, however, does not include the use of a patented composition of matter,
194
and a patented use of a composition of matter.
In 2002, Rep. Lynn Rivers introduced the Genomic Research and Diagnostic
Accessibility Act of 2002 "to provide for non-infringing uses of patents on genetic
sequence information for purposes of research and genetic diagnostic testing" but this
bill received little support. 195 Section 2 of this proposed Act provided a noncommercial research exemption, and section 3 provided exemption for medical
practitioners performing genetic diagnostic testing.196

2. ProposedLegislation for Exemption from PatentInfringement Remedies for
Human Genetic Diagnostic Testing
The legislation proposed here for exemption from patent infringement remedies
is very narrow and applies only to medical practitioners' performance of human
genetic diagnostic testing that constitutes an infringement. 197 The term "medical
practitioner" means "any natural person who is licensed by a State to provide medical
activity ... or who is acting under the direction of such person in the performance of
the medical activity."1 9 8 The proposed legislation adopts section 3 of the Genomic
Research and Diagnostic Accessibility Act of 2002.199 This section amends 35 U.S.C.
§ 287(c)(2)(A) by redefining the term "medical activity" to include "performance of a
genetic diagnostic, prognostic, or predictive test or a medical or surgical
procedure." 20 0 The term "genetic diagnostic, prognostic, or predictive test" is defined
as "any test, designed to detect disease, to predict the potential for a medical
disorder, or to predict the effectiveness of therapeutics, which uses either an ordered
listing of nucleotides comprising a portion of a human or human pathogen genetic
code or the proteins encoded by such nucleotides." 20 1 Similarly, the Secretary's
Advisory Committee on Genetics, Heath and Society ("SACGHS") distinguished the
use of human gene patents in genetic testing from use in therapeutics and
20 2
recommended that gene patent rights should not be enforced in genetic testing.
The SACGHS reasoned that "[t]he existence of multiple providers for a particular
testing would permit second-opinion testing and the sharing of samples to ensure the
quality of testing."203 Because the statutory change applies only to human genetic
diagnostic testing, human gene patents would remain enforceable for therapeutic use
2°
and would serve to stimulate investment in the biotechnology industry. 4

194

Id. § 287(c)(2)(A).

195 Genomic Research and Diagnostic Accessibility Act of 2002, H.R. 3967, 107th Cong. pmbl.
196 Id. §§ 2-3.
197

See 35 U.S.C. § 287(c).

198 See id. § 287(c)(2)(B).

199 H.R. 3967 § 3.
200 Id. § 3(a)(1).
201 See id. § 3(a)(3).
202 SACGHS Report, supra note 2, at 88.
203 _d.
204

See id.
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CONCLUSION

The Supreme Court previously concluded that Congress intended statutory
subject matter under 35 U.S.C. § 101 "to include anything under the sun that is
made by man" and that the proper forum for excluding a specific technology from
patent-eligible subject matter lies within the legislative body. 205 Congress has
previously considered, but failed to statutorily exclude human genes under section
101.206 Despite this background, in Myriad the United States District Court for the
Southern District of New York ruled that human gene patents are not patent-eligible
subject matter under 35 U.S.C. § 101.207 However, this district court's decision does
208
not lead to automatic invalidation of all existing human gene patents.
On June 16, 2010, Myriad filed a Notice of Appeal to the Federal Circuit. 20 9 On
appeal, the Federal Circuit should uphold the validity of human gene patents
including Myriad's patents-in-suit in view of long-standing legal precedent that a
new and useful composition of matter isolated from natural substances is patenteligible. 2 10 Myriad's claims on isolated DNA molecules encoding normal or mutant
forms of human BRCA1/2 are directed to compositions of matter. 211 These claims
may also be considered as manufactures because the claimed isolated DNA molecules
do not exist in nature and significantly differ in structure, function and utility from
the naturally-occurring human BRCA1/2 genes. 212 Further, Myriad's diagnostic
method claims for determining a predisposition to breast cancer using isolated DNA
molecules encoding human BRCA1/2 should be patent-eligible processes in view of
PrometheuS. 213
If the Federal Circuit affirms the district court's decision that invalidated
2 14
Myriad's gene patents-in-suit, this decision would have negative repercussions.
While statutory exclusion of human gene patents would not apply to patents issued
before the date of the enactment of the legislation, judicial exclusion would lead to
the invalidation of all human gene patents, which could unravel the foundation of
biotechnology industry. 215 Such a ruling would destroy not only decades of
205 Diamond v. Chakrabarty, 447 U.S. 303, 308, 318 (1980).
206 Genomic Research and Accessibility Act, H.R. 977, 110th Cong. § 2 (2007).
207 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515, 2010
WL 1233416, at *42, *49 (S.D.N.Y. Mar. 29, 2010) (amended April, 5, 2010).
208 See Press Release, Myriad Genetics, Inc., Federal District Court Rules Isolated DNA Claims
are Not Patentable: Myriad to Appeal Decision to the Federal Circuit Court of Appeals (March 30,
2010), available at http://investor.myriad.com/releasedetail.cfm?ReleaselD=455348
(emphasizing
that the district court's decision was limited to 15 claims in seven patents and that 164 claims in
those seven patents and additional 16 patents covering Myriad's BRCA tests were not challenged).
20) Notice of Appeal to the Federal Circuit, Ass'n for Molecular Pathology v. U.S. Patent &
Trademark Office, No. 09 Civ. 4515 (S.D.N.Y. June 16, 2010).
210 See In re Bergstrom, 427 F.2d 1394, 1402 (C.C.P.A. 1970); Merck & Co. v. Olin Mathieson
Chem. Corp., 253 F.2d 156, 162-63 (4th Cir. 1958); Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95,
103 (S.D.N.Y. 1911).
211 See Ass'n for Molecular Pathology, 2010 WL 1233416 at *31-32 (construing DNA as a
"tangible, chemical compound").
212 See Myriad's brief, supranote 65, at 30, 31.
213 See id.
214 Pollack, supra note 11, at B1.
215 See Genomic Research and Accessibility Act, H.R. 977, 110th Cong. § 2 (2007); Sherry M.
Knowles, Fixing the Legal Frameworkfor Pharmaceutica]Research, 327 SCIENCE 1083, 1084 (2010)
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investment of capital and research, undertaken in reliance on the validity of human
gene patents, but also incentives for future innovation to translate the basic research
2 16
into diagnostics and therapeutics.
Nonetheless, the district court's decision reflects the concern about the possible
adverse impact of human gene patents on patients' access to genetic testing. 217 It is
difficult to balance the public's interest in access to human gene patents and the
biotechnology industry's incentive to invest capital to translate basic research to
commercial products that ultimately benefit the public. As an alternative to a total
ban on human gene patents, this comment has proposed narrowly tailored legislation
to achieve this balance. Under the proposal, a court may grant compulsory licensing
in limited circumstances to stimulate commercialization of human gene-related
inventions such as diagnostics and therapeutics that benefit the public. In addition,
a court would prohibit enforcement of human gene patents related to diagnostic
genetic testing against medical practitioners. Thus, the proposed legislation would
safeguard patients' access to human gene patents related to genetic diagnostic
testing, and it would encourage reasonable licensing policies that maximize
commercial development of diagnostics and therapeutics to benefit the public.

(indicating that retroactive judicial invalidation of patent could constitute taking and suggesting
that "Congres should pass a law that gives an appellate court discretion to mark a decision for
prospective only, if it overrules a prior interpretation of patent statutory law.").
216 Stott & Valentine, supra note 35, at 364; Nunnally et al., supra note 35, at 215.
217 Sitting Up and Taking Notice, 28 NATURE BIOTECHNOLOGY 381, 381 (May, 2010); Testing
Time for Gene Patents,464 NATURE 957, 957 (April, 2010).

